Research Compound • 2026 Reference
SLU-PP-332 Research Compound
SLU-PP-332 is an experimental synthetic small-molecule
pan-estrogen-related receptor agonist studied for activity across
ERRα, ERRβ and ERRγ and for its role in preclinical research
involving mitochondrial biology, oxidative metabolism,
skeletal-muscle signaling and exercise-associated pathways.
Pan-ERR Agonist
ERRα / ERRβ / ERRγ
Small Molecule
Mitochondrial Research
Preclinical Research
Research Use Only
Compound Class
Synthetic Small Molecule
Research Targets
ERRα / ERRβ / ERRγ
Pharmacology
Pan-ERR Agonist
Research Status
Preclinical
What Is SLU-PP-332?
SLU-PP-332 is a synthetic research compound developed as a
pharmacological agonist of the estrogen-related receptor family of
nuclear receptors.
Published experimental work characterizes SLU-PP-332 as active
across ERRα, ERRβ and ERRγ, with greater potency
toward ERRα reported in its original characterization.
Despite sometimes being grouped with peptide research products,
SLU-PP-332 is not a peptide. It is a synthetic
small molecule used experimentally to investigate pharmacological
activation of estrogen-related receptor signaling.
How Does SLU-PP-332 Work in Research Models?
Estrogen-related receptors are transcriptional regulators associated
with cellular energy metabolism. Experimental activation of these
receptors provides researchers with a method for investigating
ERR-dependent metabolic and mitochondrial pathways.
SLU-PP-332
ERRα / ERRβ / ERRγ
Transcriptional Signaling
Metabolic & Mitochondrial Research
ERR signaling has been associated with biological processes
including oxidative phosphorylation, fatty-acid metabolism,
mitochondrial function and energy utilization in metabolically
active tissues.
SLU-PP-332 Research Areas
Published preclinical research has made SLU-PP-332 a useful
experimental tool across several areas of metabolic and
mitochondrial biology.
01
ERR Signaling
Investigation of pharmacological activation across the
ERRα, ERRβ and ERRγ nuclear-receptor family.
02
Mitochondrial Biology
Research involving mitochondrial function, cellular
respiration and pathways associated with oxidative energy
metabolism.
03
Skeletal-Muscle Research
Experimental investigation of oxidative skeletal-muscle
characteristics and exercise-associated transcriptional
responses.
04
Energy Metabolism
Research involving fatty-acid oxidation, cellular energy
utilization and ERR-regulated metabolic pathways.
SLU-PP-332 and PGC-1α
SLU-PP-332 is sometimes described online as a
“PGC-1α activator.” That description can obscure
its experimentally characterized primary pharmacology.
SLU-PP-332 is more precisely described as a
synthetic pan-ERR agonist. PGC-1 family
coactivators participate in broader transcriptional networks
relevant to ERR signaling and mitochondrial energy metabolism.
i
Research classification:
ERRα, ERRβ and ERRγ are the pharmacological receptor targets
used to characterize SLU-PP-332. PGC-1α is relevant to the
surrounding transcriptional biology rather than being presented
as the compound's direct primary target.
SLU-PP-332 and Mitochondrial Research
The connection between estrogen-related receptors and cellular
energy regulation is one reason SLU-PP-332 has attracted substantial
research interest.
ERR-regulated transcription participates in pathways associated
with mitochondrial function, oxidative phosphorylation,
fatty-acid oxidation and cellular energy metabolism.
Synthetic ERR agonists therefore provide experimental tools for
studying how pharmacological activation of these transcriptional
networks affects metabolic and mitochondrial biology in preclinical
models.
Why Is SLU-PP-332 Studied as an Exercise Mimetic?
SLU-PP-332 has received considerable research attention because
preclinical studies have examined whether pharmacological ERR
activation can reproduce selected molecular and metabolic responses
associated with aerobic exercise.
This has led to SLU-PP-332 being discussed within the experimental
“exercise mimetic” field.
!
Important distinction:
“Exercise mimetic” is a research concept. It does not establish
that SLU-PP-332 reproduces the broad cardiovascular,
neurological, musculoskeletal and metabolic effects of physical
exercise in humans.
Is SLU-PP-332 Orally Bioavailable?
Later published research identified
lack of oral bioavailability as an important
pharmacokinetic limitation of SLU-PP-332.
That limitation contributed to medicinal-chemistry research into
chemically distinct pan-ERR agonists with different pharmacokinetic
properties, including SLU-PP-915.
SLU-PP-915 subsequently demonstrated biological activity following
oral administration in mouse research, creating an important
experimental distinction between the two compounds.
Research Deep Dive
SLU-PP-332 vs SLU-PP-915
Compare ERR pharmacology, chemistry, oral activity,
mitochondrial research and published preclinical evidence.
COMPARE COMPOUNDS →
SLU-PP-332 Metabolism Research
Analytical research published in 2026 further characterized the
in-vitro metabolism of SLU-PP-332 using liver-derived experimental
systems and high-resolution mass-spectrometry techniques.
The investigators reported nine SLU-PP-332
metabolites in the experimental systems studied, including
six Phase-I metabolites and three Phase-II conjugates.
These findings contribute to analytical characterization and
metabolite identification. In-vitro metabolism studies should not
be interpreted as establishing human pharmacokinetics or clinical
safety.
SLU-PP-332 Research FAQ
What is SLU-PP-332?
SLU-PP-332 is an experimental synthetic small molecule studied
as an agonist of ERRα, ERRβ and ERRγ.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a synthetic small molecule rather than a
peptide chain.
What receptors does SLU-PP-332 target?
Published experimental research characterizes SLU-PP-332 as a
pan-estrogen-related receptor agonist with activity across
ERRα, ERRβ and ERRγ.
Is SLU-PP-332 a PGC-1α activator?
Its more precise pharmacological classification is a pan-ERR
agonist. PGC-1 family coactivators are relevant to the broader
transcriptional networks surrounding ERR signaling.
Why is SLU-PP-332 called an exercise mimetic?
Preclinical research has examined whether pharmacological ERR
activation can reproduce selected molecular responses associated
with aerobic exercise. The term describes a research concept and
does not establish substitution for exercise in humans.
Is SLU-PP-332 orally bioavailable?
Published research has identified lack of oral bioavailability
as a limitation of SLU-PP-332.
Has SLU-PP-332 demonstrated human clinical efficacy?
The research discussed here is preclinical. Laboratory and animal
findings do not establish human clinical efficacy, dosing or
safety.
Published SLU-PP-332 Research
-
Billon C, et al. (2023).
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute
Aerobic Exercise Response and Enhances Exercise Capacity.
ACS Chemical Biology.
PubMed →
-
Hampton CS, et al. (2023).
Medicinal-chemistry research involving potent pan-ERR agonists
and the subsequent development of SLU-PP-915.
PubMed Central →
-
Billon C, et al. (2026).
An orally active estrogen receptor-related receptor agonist,
SLU-PP-915, enhances aerobic exercise capacity.
PubMed →
-
Möller GM, et al. (2026).
In Vitro Metabolism and Analytical Characterization of
SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With
Doping Potential.
Rapid Communications in Mass Spectrometry.
PubMed →
Research Use Only:
SLU-PP-332 is an experimental research compound. This material
and the information presented here are intended for laboratory
research and scientific-reference purposes only. Published
laboratory and animal findings do not establish human dosing,
efficacy or safety. Not for human consumption.